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THE two most common causes of late organ allograft failure are complications associated with the long-
term use of nonspecific immunosuppression and chronic 
rejection. Incidentally. this undesirable outcome could be 
prevented by timely adoption of clinically applicable 
strategies that would result in the induction of donor-
specific tolerance (DST). We have previously advanced 
the hypothesis that stable existence of donor cell chimer-
ism in organ allograft recipients may induce DST with 
ultimate enhancement of patient and graft survival. 1.2 To 
test this hypothesis. we proceeded to augment chimerism 
in clinical organ transplant recipients by adjuvant peri-
operative unmodified donor bone marrow (BM) infu-
sion.2•3 Reported herein is the outcome of this prospec-
tive trial in which 251 study (BM-augmented) and 129 
contemporaneous controls have been accrued since its 
initiation in June 1992. 
MATERIALS AND METHODS 
A total of 219 organ allograft recipients (liver, n = 68; kidney, n = 
39; kidney + islets. n = 7; kidney + pancreas, n = 38; heart. n = 
27; lung. n = 19; small bowel, n = 18; and multivisceral. n = 4) 
have received intravenously a single perioperative dose of 3 to 6 X 
10" donor BM cellslkg body weight. The median follow up is 753 :: 
444 days. Additionally, 16 recipients (liver, n = 6; kidney. n = 4; 
kidney + islet, n = 1; and kidney + pancreas, n = 5) have received 
five consecutive (from days 0 to 4 posttransplantation) doses of 1 X 
10M BM cellslkg body weight/d, whereas 16 recipients (kidney, n = 
5; kidney + pancreas, n = 4; heart. n = 2; and lung. n = 5) have 
received three sequential infusions of 2 x 10M BM cellslkg body 
weight/d from days 0 to 2 posttransplantation. Follow up of patients 
in the multiple infusion group is 232 :: 184 days. Unavailability of 
consent to retrieve vertebral bodies (VB) from cadaveric donors 
has resulted in accrual of 129 control patients whose follow up is 
783 :: 446 days. Donor and recipient ages, sex, and HLA mis-
matches (or matches) are comparable in the study and control 
populations. Immunosuppression was with tacrolimus and steroids: 
66 patients (49 study and 17 control) also received CellCept. BM 
was isolated from the VB of cadaveric donors by a procedure 
outlined previously.2 During the course of posttransplant follow up. 
serial peripheral blood samples were obtained to ascertain the 
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presence of donor cells by flow cytometry and by molecular 
techniques." Additionally, in vitro immune monitoring was also 
performed to assess donor-specific modulation. 
RESULTS AND DISCUSSION 
The safety of BM infusion in organ allograft recipients has 
already been established.2 During the course of follow up, 
28/251 (11%) of study patients have died; none due to 
causes uniquely related to infused BM. Similarly. 21/129 
(16%) control patients have succumbed during this follow 
up (Fig lB). Furthermore. as is evident in enclosed Fig 1, 
patient and graft survival were relatively comparable in 
recipients receiving single versus multiple infusion. The 
cumulative risk of acute cellular rejection (ACR) was also 
analogous in the BM-augmented and control patients (Fig 
1C), As compared to those receiving single, there was a 
trend (albeit not statistically significant) for lowered risk of 
ACR during the initial postoperative period in the recipi-
ents of multiple BM infusions. 
Of those who are at least 1 year posttransplantation. 
89/164 (54%) of study and 43/99 (43%) control patients 
have been taken off steroids. Interestingly, as compared 
with the controls (0%). 22% of lung + BM recipients have 
been taken off steroids. Incidentally, the latter group of 
patients also had lower incidence (4%) of obliterative 
bronchiolitis as compared to the controls (33%) and a 
higher incidence of donor-specific immune modulation as 
evidenced by in vitro proliferative responses. 
At their most recent follow up, a relatively higher inci-
dence (89%) of donor cell chimerism was observed in 
BM-augmented patients as compared to controls (53%). 
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Fig 1. Kaplan-Meier analysis 
of the actuarial patient and graft 
survival and cumulative risk of 
acute cellular rejection in BM-
augmented (--) and control 
(- - -) organ allograft recipients. 
A similar analysis in patients re-
ceiving single ( ... ) or multiple 
(- . - . -) infusions of donor 
BM is also presented for com-
parative analysis. 
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Additionally, preliminary results obtained using semi-quan-
titative dot blot analysis suggested that as compared with 
controls. the level of donor cell chimerism was at least 2 to 
3 times higher in patients receiving a single BM infusion; 
this was further augmented (4 to 5 times) by the use of the 
multiple infusion protocol. 
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